Positive Results Announced for Bristol Meyer Squibb’s Plaque Psoriasis Trial

May 13, 2022

Bristol Meyer Squib (BMS) has released promising two-year results for deucravacitinib, its psoriasis therapeutic. The results show the drug was efficacious for adults with moderate to severe plaque psoriasis and was well-tolerated by patients. Psoriasis is a chronic immune-mediated skin condition with limited treatment options.

According to John Pinching of PM Live, “Overall observed safety of deucravacitinib effectively spanned 2,482 patient years of treatment and was consistent with previously presented pivotal phase 3 trials. Adverse events continued to be predominantly mild or moderate, with the most frequent being nasopharyngitis, upper respiratory tract infections or headaches.”